| pubmed-article:8032300 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8032300 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8032300 | lifeskim:mentions | umls-concept:C0007137 | lld:lifeskim |
| pubmed-article:8032300 | lifeskim:mentions | umls-concept:C0460004 | lld:lifeskim |
| pubmed-article:8032300 | lifeskim:mentions | umls-concept:C1520381 | lld:lifeskim |
| pubmed-article:8032300 | lifeskim:mentions | umls-concept:C0806692 | lld:lifeskim |
| pubmed-article:8032300 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:8032300 | lifeskim:mentions | umls-concept:C0012872 | lld:lifeskim |
| pubmed-article:8032300 | lifeskim:mentions | umls-concept:C1521871 | lld:lifeskim |
| pubmed-article:8032300 | lifeskim:mentions | umls-concept:C0332183 | lld:lifeskim |
| pubmed-article:8032300 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8032300 | pubmed:dateCreated | 1994-8-16 | lld:pubmed |
| pubmed-article:8032300 | pubmed:abstractText | Amplification of 11q13 DNA markers, particularly hst-1/FGF4 oncogene and the bcl-1 locus, was evaluated in 178 head and neck squamous cell carcinomas (SCCs) by Southern blot and slot blot hybridisation. Coamplification of hst-1/FGF4 and bcl-1 genes was found in 57% of primary tumours and in 60% of the 89 metastatic lymph nodes tested. The pattern of amplification was significantly similar in matched sets of primary SCCs and metastatic lymph nodes. Levels of amplification, quantified by densitometric analysis of slot blots, ranged from 2 to 18-fold normal gene dosage. Also, c-myc oncogene (8q24) was found amplified less frequently, since 7% of 169 SCCs tested contained amplification of this gene, the level of which ranged from 2 to 8-fold. Hst-1/bcl-1 gene amplification was observed more frequently in the tumours arising from the hypopharynx. Coamplification of hst-1 and bcl-1 genes was significantly positively associated with tumours with nodal involvement (P = 0.001). Incidence of hst-1/bcl-1 gene amplification is higher in the tumours with a clinical stage III or IV. Hst-1/bcl-1 gene amplification was not related to tumour differentiation or local invasiveness. This prospective study shows that amplification of 11q13 DNA markers is a prominent event occurring in head and neck SCC and may contribute to the pathogenesis and evolution of a subset of patients bearing this type of cancer. | lld:pubmed |
| pubmed-article:8032300 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8032300 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8032300 | pubmed:citationSubset | D | lld:pubmed |
| pubmed-article:8032300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8032300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8032300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8032300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8032300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8032300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8032300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8032300 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8032300 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8032300 | pubmed:issn | 0964-1955 | lld:pubmed |
| pubmed-article:8032300 | pubmed:author | pubmed-author:AbecassisJJ | lld:pubmed |
| pubmed-article:8032300 | pubmed:author | pubmed-author:EbenAA | lld:pubmed |
| pubmed-article:8032300 | pubmed:author | pubmed-author:MullerDD | lld:pubmed |
| pubmed-article:8032300 | pubmed:author | pubmed-author:BronnerGG | lld:pubmed |
| pubmed-article:8032300 | pubmed:author | pubmed-author:LidereauRR | lld:pubmed |
| pubmed-article:8032300 | pubmed:author | pubmed-author:MethlinGG | lld:pubmed |
| pubmed-article:8032300 | pubmed:author | pubmed-author:MillonRR | lld:pubmed |
| pubmed-article:8032300 | pubmed:author | pubmed-author:EngelmannAA | lld:pubmed |
| pubmed-article:8032300 | pubmed:author | pubmed-author:FleschHH | lld:pubmed |
| pubmed-article:8032300 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8032300 | pubmed:volume | 30B | lld:pubmed |
| pubmed-article:8032300 | pubmed:geneSymbol | c-myc | lld:pubmed |
| pubmed-article:8032300 | pubmed:geneSymbol | bcl-1 | lld:pubmed |
| pubmed-article:8032300 | pubmed:geneSymbol | prad-1 | lld:pubmed |
| pubmed-article:8032300 | pubmed:geneSymbol | FGH4 | lld:pubmed |
| pubmed-article:8032300 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8032300 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8032300 | pubmed:pagination | 113-20 | lld:pubmed |
| pubmed-article:8032300 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:meshHeading | pubmed-meshheading:8032300-... | lld:pubmed |
| pubmed-article:8032300 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8032300 | pubmed:articleTitle | Frequent amplification of 11q13 DNA markers is associated with lymph node involvement in human head and neck squamous cell carcinomas. | lld:pubmed |
| pubmed-article:8032300 | pubmed:affiliation | Centre de Lutte contre le Cancer Paul Strauss, Strasbourg, France. | lld:pubmed |
| pubmed-article:8032300 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8032300 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8032300 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8032300 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8032300 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8032300 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8032300 | lld:pubmed |
